Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
The Lancet. Oncology.
Times cited: 315
Analysis of dermatologic events in vemurafenib-treated patients with melanoma.
Times cited: 84
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
The New England journal of medicine.
Times cited: 568